Reprieve Cardiovascular announced it closed an oversubscribed $61 million Series B financing round. The round was led by Deerfield Management with participation from Arborteum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, Cadence Capital and an undisclosed strategic investor. Funding combines equity investment with a debt facility to support growth. Proceeds will fund the pivotal FASTR II clinical trial and commercial readiness activities. The Reprieve system is designed to personalize decongestion management for heart failure patients. It removes excess fluid and sodium while replenishing saline to support kidney function. The system uses real-time physiological monitoring and automated therapy recommendations. This enables physicians to tailor treatment and reduce clinician workload. FASTR II follows the FASTR pilot study, which met its primary efficacy and safety endpoints. The pivotal trial will enroll up to 400 patients in the US and Europe. It will compare Reprieve’s system against optimal diuretic therapy in acute decompensated heart failure cases. Results will support a future FDA premarket approval submission. CEO Mark Pacyna said the funding positions the company to deliver clinical and economic evidence needed for regulatory clearance and global adoption.